BeOne Medicines Ltd (6160) Gets a Buy from Nomura
Junshi Biosciences Shareholders Approve H-Share Buyback Mandate
Junshi Biosciences Completes RMB300 Million Technology Innovation Bond Issuance
Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC
Junshi Biosciences Wins NMPA Nod to Expand Toripalimab Use in Early-Stage Lung Cancer
Shanghai Junshi says China regulator accepts label expansion filing for toripalimab chemo in resectable stage II-III NSCLC